ATE490771T1 - Therapeutisches mittel für keratokonjunktive erkrankungen - Google Patents

Therapeutisches mittel für keratokonjunktive erkrankungen

Info

Publication number
ATE490771T1
ATE490771T1 AT04793171T AT04793171T ATE490771T1 AT E490771 T1 ATE490771 T1 AT E490771T1 AT 04793171 T AT04793171 T AT 04793171T AT 04793171 T AT04793171 T AT 04793171T AT E490771 T1 ATE490771 T1 AT E490771T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
ylmethoxy
benzimidazol
thiazolidine
dione
Prior art date
Application number
AT04793171T
Other languages
English (en)
Inventor
M Nakamura
S Hirai
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE490771T1 publication Critical patent/ATE490771T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04793171T 2003-10-24 2004-10-22 Therapeutisches mittel für keratokonjunktive erkrankungen ATE490771T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003364864 2003-10-24
PCT/JP2004/016063 WO2005039574A1 (ja) 2003-10-24 2004-10-22 角結膜障害の治療剤

Publications (1)

Publication Number Publication Date
ATE490771T1 true ATE490771T1 (de) 2010-12-15

Family

ID=34510137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04793171T ATE490771T1 (de) 2003-10-24 2004-10-22 Therapeutisches mittel für keratokonjunktive erkrankungen

Country Status (16)

Country Link
US (1) US7358255B2 (de)
EP (1) EP1679074B1 (de)
JP (1) JP4217832B2 (de)
KR (1) KR101154175B1 (de)
CN (1) CN1870997B (de)
AT (1) ATE490771T1 (de)
CA (1) CA2543452C (de)
CY (1) CY1111191T1 (de)
DE (1) DE602004030470D1 (de)
DK (1) DK1679074T3 (de)
ES (1) ES2357801T3 (de)
PL (1) PL1679074T3 (de)
PT (1) PT1679074E (de)
SI (1) SI1679074T1 (de)
TW (1) TWI343256B (de)
WO (1) WO2005039574A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060118520A (ko) * 2003-10-29 2006-11-23 산텐 세이야꾸 가부시키가이샤 각결막장해 치료제
WO2006064825A1 (ja) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. ドライアイ治療剤
JP5186217B2 (ja) 2005-11-28 2013-04-17 千寿製薬株式会社 Pparアゴニスト含有医薬
ATE525374T1 (de) 2005-12-13 2011-10-15 Incyte Corp Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
JP5247686B2 (ja) * 2007-05-21 2013-07-24 千寿製薬株式会社 PPARδアゴニスト含有医薬
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
JP2009227668A (ja) * 2008-02-25 2009-10-08 Santen Pharmaceut Co Ltd 角膜上皮バリア機能亢進剤
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
JP6172939B2 (ja) * 2009-05-22 2017-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Jak阻害薬としての3−[4−(7h−ピロロ[2,3−d]ピリミジン−4−イル)−1h−ピラゾール−1−イル]オクタン−またはヘプタン−ニトリル
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
KR102303885B1 (ko) 2010-05-21 2021-09-24 인사이트 홀딩스 코포레이션 Jak 저해제에 대한 국소 제형
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
RS62329B1 (sr) 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
TR201820520T4 (tr) 2013-03-06 2019-01-21 Incyte Holdings Corp Bir jak inhibitörü yapmaya yönelik prosesler ve ara ürünler.
DK3030227T3 (da) 2013-08-07 2020-04-20 Incyte Corp Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CA3095487A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264586B1 (de) * 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin-Derivate zur Behandlung von Komplikationen bei Diabetes
JP3072227B2 (ja) 1994-08-01 2000-07-31 株式会社クボタ 田植機の粉粒体供給装置
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
JP4339402B2 (ja) 1996-12-31 2009-10-07 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用
EP0909558A3 (de) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Ophthalmische Lösung enthaltend ein Chromanderivat
JPH11130675A (ja) 1997-08-29 1999-05-18 Santen Pharmaceut Co Ltd クロマン誘導体含有点眼液
JP2001039976A (ja) 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP2002220336A (ja) 2000-11-22 2002-08-09 Sankyo Co Ltd 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
JP4090013B2 (ja) 2000-12-26 2008-05-28 第一三共株式会社 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物
KR20060118520A (ko) * 2003-10-29 2006-11-23 산텐 세이야꾸 가부시키가이샤 각결막장해 치료제

Also Published As

Publication number Publication date
CY1111191T1 (el) 2015-06-11
CN1870997A (zh) 2006-11-29
PT1679074E (pt) 2011-03-03
KR101154175B1 (ko) 2012-06-14
KR20060100440A (ko) 2006-09-20
US7358255B2 (en) 2008-04-15
TW200518750A (en) 2005-06-16
JP2005145961A (ja) 2005-06-09
EP1679074A1 (de) 2006-07-12
EP1679074B1 (de) 2010-12-08
CA2543452A1 (en) 2005-05-06
ES2357801T3 (es) 2011-04-29
DE602004030470D1 (de) 2011-01-20
WO2005039574A1 (ja) 2005-05-06
EP1679074A4 (de) 2009-03-25
WO2005039574A8 (ja) 2005-06-23
CA2543452C (en) 2012-03-13
DK1679074T3 (da) 2011-03-21
TWI343256B (en) 2011-06-11
PL1679074T3 (pl) 2011-05-31
US20070060628A1 (en) 2007-03-15
CN1870997B (zh) 2011-05-04
JP4217832B2 (ja) 2009-02-04
SI1679074T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
ATE490771T1 (de) Therapeutisches mittel für keratokonjunktive erkrankungen
PE20090837A1 (es) Nuevos compuestos quimicos
DE60316810T2 (de) 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
IL263314A (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20051146A1 (es) Compuestos heterociclicos anticitocina
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
FI2440547T3 (fi) Uusia silmukointimekanismia estäviä kemiallisia molekyylejä silmukointivirheistä johtuvien sairauksien hoitoon
CA2634676A1 (en) Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp
EP1646614A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
HRP20141048T1 (hr) Spojevi, pripravci i metode
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
PE20090949A1 (es) Compuesto heterociclico y composicion farmaceutica del mismo
HRP20120919T1 (hr) 2-[4-(pirazol-4-ilalkil)piperazin-1-il]-3-fenilpirazini i -piridini i 3-[4-(pirazol-4-ilalkil)piperazin-1-il]-2-fenilpiridini kao antagonisti receptora 5-ht7
CN111349053A (zh) 赖氨酸牙龈卟啉菌蛋白酶的抑制剂
PE20080271A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
RU2008129723A (ru) Ингибиторы ccr9 активности
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
RU2010102899A (ru) Новые замещенные пиперидоны в качестве индукторов hsp
DE69717969D1 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
NO20082922L (no) Terapeutisk middel for keratokonjunktive lidelser
PE20060618A1 (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1679074

Country of ref document: EP